- Home
- VIPS vs MDGL Comparison
VIPS vs MDGL Comparison
Compare VIPS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIPS
- MDGL
- Stock Information
- Founded
- VIPS 2008
- MDGL 2011
- Country
- VIPS China
- MDGL United States
- Employees
- VIPS N/A
- MDGL N/A
- Industry
- VIPS Catalog/Specialty Distribution
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- VIPS Consumer Discretionary
- MDGL Health Care
- Exchange
- VIPS Nasdaq
- MDGL Nasdaq
- Market Cap
- VIPS 6.8B
- MDGL 6.4B
- IPO Year
- VIPS 2012
- MDGL N/A
- Fundamental
- Price
- VIPS $13.44
- MDGL $293.64
- Analyst Decision
- VIPS Buy
- MDGL Buy
- Analyst Count
- VIPS 6
- MDGL 14
- Target Price
- VIPS $16.20
- MDGL $351.67
- AVG Volume (30 Days)
- VIPS 2.8M
- MDGL 413.3K
- Earning Date
- VIPS 02-26-2025
- MDGL 02-26-2025
- Dividend Yield
- VIPS 3.19%
- MDGL N/A
- EPS Growth
- VIPS 17.49
- MDGL N/A
- EPS
- VIPS 2.15
- MDGL N/A
- Revenue
- VIPS $15,663,477,774.00
- MDGL $76,813,000.00
- Revenue This Year
- VIPS N/A
- MDGL N/A
- Revenue Next Year
- VIPS N/A
- MDGL $194.49
- P/E Ratio
- VIPS $6.27
- MDGL N/A
- Revenue Growth
- VIPS N/A
- MDGL N/A
- 52 Week Low
- VIPS $11.50
- MDGL $168.25
- 52 Week High
- VIPS $20.19
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- VIPS 51.79
- MDGL 45.07
- Support Level
- VIPS $12.98
- MDGL $266.44
- Resistance Level
- VIPS $13.30
- MDGL $343.97
- Average True Range (ATR)
- VIPS 0.36
- MDGL 17.83
- MACD
- VIPS 0.03
- MDGL -4.57
- Stochastic Oscillator
- VIPS 84.26
- MDGL 35.08
About VIPS Vipshop Holdings Limited
Vipshop is a Leading Chinese online discount retailer offering branded products at attractive discounts ranging from 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurements, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with over 29,000 global partners as of Dec. 31, 2023. As of March 31, 2024, Eric Ya Shen, chairman and CEO, has 63.1% voting rights and a 30.9% stake while Arthur Xiaobo Hong, vice chairman and COO, has a 17.6% stake. Leading Chinese social media firm and strategic shareholder Tencent also holds an 11.8% interest.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.